Abstract
Oncolytic viruses have entered the field of pediatric clinical research with the first early phase clinical trial recently published. Based on promising pre-clinical studies, the oncolytic parvovirus H-1 (H-1PV) has been applied to adult glioblastoma patients in a phase I/IIa clinical trial, indicating clinical safety of intracranial and intravenous virus application. Here, we characterized the cytotoxic effects induced by the oncolytic parvovirus H-1 in conventional pediatric high-grade glioma (HGG) cell culture models and neurosphere cultures derived thereof.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
